nach oben

Drugs

Erschienen in:

01.08.2019 | AdisInsight Report

Camrelizumab: First Global Approval

verfasst von: Anthony Markham, Susan J. Keam

Erschienen in: Drugs | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Abstract

Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma. The drug is also being investigated as a treatment for various other malignancies, including B cell lymphoma, oesophageal squamous cell carcinoma, gastric/gastroesophageal junction cancer, hepatocellular carcinoma, nasopharyngeal cancer and non-squamous, non-small cell lung cancer. This article summarizes the milestones in the development of camrelizumab leading to this first approval for classical Hodgkin lymphoma.

Mo H, Huang J, Xu J, et al. Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. Br J Cancer. 2018;119(5):538–45.CrossRef

Jiangsu Hengrui Medicine. Announcement on obtaining new drug certificate and drug registration approval [media release]. 31 May 2019. http://cfi.cn/p20190531000358.html.

Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.CrossRef

Jiangsu Hengrui Medicine Co. Ltd. Camrelizumab: Chinese prescribing information. Lianyungang: Jiangsu Hengrui Medicine Co. Ltd; 2019.

Hogan Lovells. The China Food and Drug Administration pushes forward on conditional approval and compassionate use of new drugs [media release]. 17 Jan 2018. https://www.lexology.com/library/detail.aspx?g=73ce9342-8178-4b42-9c31-389edf0278c1.

Incyte Corporation. Incyte announces global license agreement with Jiangsu Hengrui Medicine for SHR-1210, an investigational anti-PD-1 monoclonal antibody [media release]. 2 Sep 2015. http://www.incyte.com.

Incyte Corporation. Form 10-Q quarterly report for the quarterly period ended 31 March 2018. 2018. https://investor.incyte.com/static-files/9a5c18d8-681c-4212-9bf3-c82405b7754b. Accessed 21 June 2019.

LSK Biopharma, Jiangsu Hengrui Medicine. LSK BioPharma and Jiangsu Hengrui Medicine announce global clinical collaboration to evaluate the combination of anti-angiogenesis and immuno-oncology therapy for patients with advanced hepatocellular carcinoma (HCC) [media release]. 21 Oct 2018. http://www.lskbiopharma.com.

Nie J, Wang C, Liu Y, et al. Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed/refractory classical Hodgkin Lymphoma. J Clin Oncol. 2019. http://doi.org/10.1200/jco.18.02151.CrossRef

10.

Zhu J, Feng J, Chen X, et al. A phase II study of SHR-1210, an antipd-1 antibody, in Chinese patients with relapsed/refractory classic Hodgkin Lymphoma [abstract no. T026 (0025)]. HemaSphere. 2018;2(Suppl. 3):41.

11.

Zhang W, Liu Y, Mei Q, et al. Safety and efficacy of GVD and anti-PD-1 (SHR-1210) regimen with or without low-dose decitabine priming for refractory bulky and aggressive primary mediastinal large B-cell lymphoma [abstract no. 7556]. J Clin Oncol. 2018;36(15 Suppl.).CrossRef

12.

Pang Q, Li X, Zhang W, et al. Safety and effect of radiation therapy combined with anti-PD-1 antibody SHR-1210 as first-line treatment on patients with intolerable concurrent chemoradiotherapy esophageal cancer: a phase 1b clinical trial [abstract no. SU_9_2089]. Int J Radiat Oncol Biol Phys. 2018;102(3 Suppl.):e39.CrossRef

13.

Jing Z, Du D, Zhang N, et al. Combination of radiation therapy and anti-PD-1 antibody SHR-1210 in treating patients with Esophageal Squamous Cell Cancer [abstract no. SU_8_2071]. Int J Radiat Oncol Biol Phys. 2018;102(3 Suppl.):e31.CrossRef

14.

Huang J, Xu B, Mo H, et al. Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma. Clin Cancer Res. 2018;24(6):1296–304.CrossRef

15.

Shen L, Peng Z, Zhang YQ, et al. Camrelizumab combined with capecitabine and oxaliplatin followed by camrelizumab and apatinib as first-line therapy for advanced or metastatic gastric or gastroesophageal junction cancer: updated results from a multicenter, open label phase II trial [abstract no. 4031]. J Clin Oncol. 2019;37(15 Suppl.).CrossRef

16.

Data on file, Jiangsu Hengrui Medicine, 2019.

17.

Xu J, Zhang Y, Jia R, et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study. Clin Cancer Res. 2019;25(2):515–23.CrossRef

18.

Huang J, Mo H, Zhang W, et al. Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China. Cancer. 2019;125(5):742–9.CrossRef

19.

Qin SK, Ren ZG, Meng ZQ, et al. A randomized multicentered phase II study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable to prior systemic treatment [abstract no. LBA27]. Ann Oncol. 2018;29(Suppl. 8):viii719–20.

20.

Fang W, Yang Y, Ma Y, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018;19(10):1338–50.CrossRef

21.

Zhou C, Gao G, Wu F, et al. A phase Ib study of SHR-1210 plus Apatinib for heavily previously treated advanced nonsquamous non-small cell lung cancer (NSCLC) patients [abstract no. e21017]. J Clin Oncol. 2018;36(15 Suppl.).

22.

Chen X, Ma L, Wang X, et al. Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210. Cancer Biol Med. 2019;16(1):173–81.CrossRef

23.

Wu F, Gao G, Zhou C, et al. A phase III, randomized, open-label, multicenter study of SHR-1210 (anti-PD-1 antibody) in combination with pemetrexed and carboplatin as first line therapy in subjects with advanced/metastatic non-squamous non-small cell lung cancer [abstract no. 1505TiP]. Ann Oncol. 2018;29(Suppl. 8):viii545.

Titel: Camrelizumab: First Global Approval
verfasst von: Anthony Markham
Susan J. Keam
Publikationsdatum: 01.08.2019
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 12/2019
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-019-01167-0

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Camrelizumab: First Global Approval

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2019

Innovations in Oral Therapies for Inflammatory Bowel Disease

Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation

Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies

Correction to: Tiotropium/Olodaterol: A Review in COPD

Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors

Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax® Tetra/Flucelvax Quadrivalent®): A Review in the Prevention of Influenza